Acadia Pharmaceuticals (ACAD) PT Raised to $42 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $28.10 -0.99%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald analyst Sarah James raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $42.00 (from $36.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential
- Parker-Hannifin (PH) PT Raised to $1,218 at Bernstein SocGen Group
- Appian Corp. (APPN) PT Raised to $42 at DA Davidson as Execution Improves
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
